Since both PI3K/Akt and mitogen-activated protein kinase (MAPK) signaling pathways are involved in the modulation of cell survival, proliferation, migration, and invasion [37,38,39], the anti-tumor activity of rLj-112 might be attributed to its inhibition on the EGFR and its downstream PI3K/Akt and MAPK signaling pathways (Figure 9). The gene discussed is EGFR; the disease is neoplasm.